Trial Profile
Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Nov 2015
Price :
$35
*
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 13 Nov 2015 Results published in the Antiviral Therapy
- 09 Nov 2015 New trial record